Key Points
- Tech heavyweights including Peter Thiel, Jeff Bezos, and Sam Altman are pouring immense fortunes into anti-aging biotechs like Altos Labs, Calico, and Retro Biosciences.
- Korean broadcaster SBS spotlighted the trend through its data-focused 'O-Graph' feature, tracking how cellular reprogramming and AI are advancing from animal testing to early human clinical trials.
- The coverage reflects growing global and Korean fascination with longevity science, questioning where legitimate medical breakthroughs end and elite commercialization begins.
Summary Can humanity conquer aging and buy eternal life with wealth? Silicon Valley's tech titans seem to think so, and their multi-billion-dollar investments into anti-aging research are drawing widespread attention from Korean media and audiences curious about the future of longevity science.
In a recent special series titled 'O-Graph' (오그랲) by major Korean broadcaster SBS—a visual journalism series that breaks down complex global developments using data and graphs—reporter Ahn Hye-min explored the intersection of high finance and biotechnology. Palantir co-founder Peter Thiel has spearheaded this mindset for over two decades, openly framing death and biological decline not as inevitable human destiny, but as an engineering and medical problem waiting to be solved.
The movement has expanded well beyond theoretical Silicon Valley philosophy into concrete, capital-heavy ventures. Prominent tech leaders are pouring vast fortunes into dedicated longevity biotechs: Amazon's Jeff Bezos backed Altos Labs; Alphabet/Google established Calico; Coinbase founders launched NewLimit; and OpenAI CEO Sam Altman invested heavily in Retro Biosciences.
Crucially, as highlighted in the coverage, these initiatives have evolved past speculative concepts. Research into 'partial cellular reprogramming'—a technique aimed at restoring aged cells to a biologically youthful state—has progressed from laboratory animal trials to early-stage human clinical trials. Furthermore, researchers are deploying advanced artificial intelligence to discover optimized cellular combinations and refine reprogramming factors.
In South Korea, where the broader public closely follows rapid advancements in AI, health-tech, and futuristic lifestyle trends, the idea of tech moguls racing to unlock biological immortality has ignited fascinating debates. While the science represents genuine medical hope, it also raises provocative questions about whether the dream of conquering death will ultimately become an ultra-exclusive luxury business reserved for the world's wealthiest elite.
Sponsored · Ad